Processa Pharmaceuticals, Inc., a company operating within the Health Care sector, specializes in the development of pharmaceutical products aimed at addressing the survival and quality of life needs of patients with unmet medical needs. Listed on the Nasdaq stock exchange, the company’s financial metrics and recent performance provide insight into its current market position.
As of January 5, 2026, Processa Pharmaceuticals’ stock closed at $2.93. Over the past year, the stock has experienced significant volatility, with a 52-week high of $24.475 on January 6, 2025, and a low of $2.75 on December 15, 2025. This wide range in stock price reflects the market’s fluctuating perception of the company’s value and potential.
The company’s market capitalization stands at $6,638,700 USD, indicating a relatively modest valuation in the pharmaceutical industry. A notable aspect of Processa Pharmaceuticals’ financial metrics is its negative price-to-earnings (P/E) ratio of -0.084. This negative ratio suggests that the company is currently not generating earnings, which is a critical factor for investors assessing the company’s profitability and growth potential.
Additionally, the price-to-book (P/B) ratio of 1.04 indicates that the market value of the company’s equity is slightly above its book value. This ratio provides a measure of the market’s valuation of the company relative to its net asset value, suggesting a modest premium over the book value.
As of the latest update on December 26, 2025, Processa Pharmaceuticals has not issued any new announcements. This lack of recent updates may contribute to the uncertainty and volatility observed in the company’s stock price.
In summary, Processa Pharmaceuticals, Inc. is a pharmaceutical company focused on developing drugs for patients with unmet medical needs. Despite its modest market capitalization and negative earnings, the company’s equity value is marginally above its book value. The significant fluctuations in its stock price over the past year highlight the challenges and uncertainties faced by the company in the competitive pharmaceutical industry.
